0001213900-23-000912.txt : 20230104 0001213900-23-000912.hdr.sgml : 20230104 20230104172148 ACCESSION NUMBER: 0001213900-23-000912 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230104 DATE AS OF CHANGE: 20230104 EFFECTIVENESS DATE: 20230104 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-469705 FILM NUMBER: 23508023 BUSINESS ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 BUSINESS PHONE: 551-578-2261 MAIL ADDRESS: STREET 1: 1 ROCKEFELLER PLAZA, SUITE 1039 CITY: NEW YORK STATE: NY ZIP: 10020 D 1 primary_doc.xml X0708 D LIVE 0001711786 Hoth Therapeutics, Inc. 1 ROCKEFELLER PLAZA SUITE 1039 NEW YORK NY NEW YORK 10020 (646) 756-2997 NEVADA None None Corporation true Robb Knie 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Executive Officer Director Chief Executive Officer and President David Briones 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Executive Officer Chief Financial Officer David Sarnoff 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Director Graig Springer 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Director Wayne Linsley 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Director Jeff Pavell 1 Rockefeller Plaza Suite 1039 New York NY NEW YORK 10020 Director Biotechnology Decline to Disclose 06b false 2023-01-03 false true true true false 0 H.C. Wainwright & Co., LLC 375 None None 430 PARK AVENUE NEW YORK NY NEW YORK 10020 NY NEW YORK false 10000000 10000000 0 false 1 700000 0 Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes (i) a management fee of $100,000; (ii) non-accountable expenses of $20,000; (iii) accountable expenses of $50,000; and (iv) 100,000 placement agent warrants. 0 false Hoth Therapeutics, Inc. /s/ Robb Knie Robb Knie Chief Executive Officer 2023-01-04